Online citations, reference lists, and bibliographies.
← Back to Search

Hétérogénéité Moléculaire Des Mésothéliomes Pleuraux Malins

R. Tranchant, François Montagne, Marie-Claude Jaurand, D. Jean
Published 2017 · Medicine, History

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma (MPM) is predominantly an occupational cancer, most often linked to asbestos exposure. Malignant pleural mesothelioma prognosis is poor with a short survival median, due to the aggressiveness of tumor cells and the weak efficiency of conventional anti-cancer therapies. Clinical, histological, and molecular data suggest tumor heterogeneity between patients as it was also shown for other cancer types. Consequently, there is an urgent need to develop new therapies that take into account this heterogeneity and the molecular characteristics of malignant pleural mesothelioma, in particular by identifying new anti-cancer drugs targeting the molecular specificities of each malignant pleural mesothelioma. Malignant pleural mesothelioma is characterized by numerous molecular alterations at the chromosomal, genetic and epigenetic levels. Molecular classification based on gene expression profile has firstly defined two tumor groups, C1 and C2, and more recently, four groups. By integrating genetic and transcriptomic analysis, a C2LN tumor subgroup of the C2 group has been identified and characterized. In addition to tumor heterogeneity between patients, intra-tumor heterogeneity is supported by several evidences. Most therapeutic strategies that take into account the tumor molecular characteristics have focused on targeted therapies based on mutated genes. A more appropriate strategy would be to consider better-defined tumor groups on the basis of several molecular alterations types as it has been proposed for the C2LN subgroup. A robust definition of homogeneous tumor groups sharing common molecular characteristics is necessary for the development of effective precision medicine for malignant pleural mesothelioma.
This paper references
10.1158/1078-0432.CCR-16-1971
Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma
R. Tranchant (2016)
10.1016/j.ajpath.2010.10.039
Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma.
D. Jean (2011)
10.1080/10937404.2011.556051
Role of Mutagenicity in Asbestos Fiber-Induced Carcinogenicity and Other Diseases
Sarah X. L. Huang (2011)
10.1200/JCO.2017.35.18_SUPPL.LBA8507
Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial
A. Scherpereel (2017)
10.1126/scitranslmed.3008639
Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship
I. Shapiro (2014)
10.1159/000339259
Malignant Pleural Mesothelioma: From the Bench to the Bedside
P. Astoul (2012)
10.2217/LMT.15.21
Causes and pathophysiology of malignant pleural mesothelioma
D. Jean (2015)
10.1371/journal.pone.0018828
Losses of Both Products of the Cdkn2a/Arf Locus Contribute to Asbestos-Induced Mesothelioma Development and Cooperate to Accelerate Tumorigenesis
D. Altomare (2011)
10.21037/tlcr.2017.06.06
Targeting the epigenome in malignant pleural mesothelioma.
Kaitlin McLoughlin (2017)
10.1016/B978-0-12-386456-7.05311-9
Thoracic Neoplasia–Mesothelioma
D. Jean (2014)
10.1073/pnas.1612074113
High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma
Yoshie Yoshikawa (2016)
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
10.1016/j.ccell.2014.12.001
Biological and therapeutic impact of intratumor heterogeneity in cancer evolution.
N. McGranahan (2015)
10.1038/sj.onc.1206593
Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours
J. Fleury-Feith (2003)
10.1016/j.jtho.2017.02.013
The Immune Microenvironment, Genome‐wide Copy Number Aberrations, and Survival in Mesothelioma
B. Thapa (2017)
10.1038/onc.2013.351
Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma
A. Tallet (2014)
10.5858/arpa.2011-0215-RA
Molecular changes in mesothelioma with an impact on prognosis and treatment.
D. Jean (2012)
10.1080/2162402X.2016.1278330
Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma
K. Kiyotani (2017)
10.1016/j.lungcan.2016.07.011
Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma.
M. Hamasaki (2016)
10.1080/10937404.2016.1193361
Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles
P. Andujar (2016)
10.1158/0008-5472.CAN-09-1595
Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.
Y. Goto (2009)
10.1080/15384047.2016.1145850
Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration
A. Borczuk (2016)
10.1007/978-3-642-10862-4_8
Chemotherapy and radiotherapy for mesothelioma.
X. Dhalluin (2011)
10.1158/0008-5472.CAN-08-2586
Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome.
B. Christensen (2009)
10.1093/mutage/get008
Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.
P. Andujar (2013)
10.5858/arpa.2010-0604-RA
Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma.
P. Betta (2012)
10.1038/onc.2017.147
E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells
T. Kato (2017)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1165/rcmb.2009-0060OC
MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications.
Sara Busacca (2010)
10.1186/s12967-014-0301-3
Evaluation of clonal origin of malignant mesothelioma
Sabahattin Comertpay (2014)
10.1016/S0272-5231(05)70074-5
Anatomy of the pleura.
N. Wang (1998)
10.1164/rccm.201210-1911OC
Pleural mesothelioma and occupational coexposure to asbestos, mineral wool, and silica.
A. Lacourt (2013)
10.1158/1078-0432.CCR-13-2429
Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition
A. de Reyniès (2014)
10.1016/S0002-9440(10)62492-3
Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling.
G. Gordon (2005)
10.3978/j.issn.2072-1439.2014.05.03
Management of malignant pleural mesothelioma-The European experience.
I. Opitz (2014)
10.1517/14656560802631285
Chemotherapy of malignant pleural mesothelioma
P. Bertino (2009)
10.1038/nrc.2017.42
Novel insights into mesothelioma biology and implications for therapy
T. Yap (2017)
10.1378/CHEST.125.5.1843
Gene expression profiling identifies matriptase overexpression in malignant mesothelioma.
C. Hoang (2004)
10.5858/arpa.2012-0214-OA
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.
A. Husain (2013)
10.1158/0008-5472.CAN-10-0190
Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma.
B. Christensen (2010)
10.1038/ng.3520
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
R. Bueno (2016)
10.1093/annonc/mdv101
Searching for targets for the systemic therapy of mesothelioma.
R. Stahel (2015)
10.1158/0008-5472.CAN-14-1328
Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.
Jinfei Xu (2014)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar